Standard product for detection of clinical drug-resistant genes in intestinal cancer and application thereof

Abstract

The invention provides a standard product for detection of clinical drug-resistant genes in intestinal cancer and application thereof. The standard product comprises a minimum detection limit reference product, the minimum detection limit reference product at least comprises a DNA mixture of two different levels of mutation frequencies, the DNA mixture of each level of mutation frequency comprises mutation sites shown in the following table 1. By using a DNA mixture containing multiple gene mutation sites related to the mutation of the intestinal cancer as a minimum detection limit reference product, and the standard product comprises the DNA mixture of at least two levels of mutation frequencies, which can be able to detect whether mutations can be detected and the frequencies of mutation can be detected or not when kits from different manufactures are used for corresponding gene mutation, thus the accuracy and reliability of detection results of each kit can be verified, and thereby relatively accurate guidance for clinical medication can be provided.

Description

technical field [0001] The invention relates to the field of intestinal cancer detection kits, in particular to a standard product for clinical drug resistance gene detection of intestinal cancer and its application. Background technique [0002] In recent years, targeted therapy has effectively controlled the mortality of tumors. Targeted therapy has the advantages of high selectivity and low toxicity, and can guide clinical medication for a long time. Its mechanism of action is to design a combination of drugs for the unique target of tumor cells, avoiding the shortcomings of traditional treatment methods, so as to achieve the goal of inhibiting tumor cell division and proliferation. For patients, it not only prolongs the survival time of patients, but also improves the quality of life of patients. [0003] At present, there are many genes related to tumor or cancer mutations that have been clinically identified, and when these genes are mutated, the sensitivity of cells ...

AI Technical Summary

Problems solved by technology

[0005] The main purpose of the present invention is to provide a standard product for clinical drug resistance gene detection of intestinal cancer and its application, so as to solve the problem that the detection results of the detection kit for intestinal cancer gene mutation in the prior art are diverse and lack clinical guidance significance

Images